Patient Guide: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 228 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06564844
Status: 🟢 Enrolling Now
Condition: Non-small Cell Lung Cancer
Phase: PHASE3

Where You Can Participate

This study is available at 228 locations across the country.

Top locations include:
  • • Gilbert, Arizona
  • • Phoenix, Arizona
  • • Prescott, Arizona
  • • And 225 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features - Join Clinical Trial NCTNCT06564844

How to Join This Clinical Trial - NCTNCT06564844

Learn how to participate in this PHASE3 trial studying an investigational therapy for Non-small Cell Lung Cancer. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Non-small Cell Lung Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Non-small Cell Lung Cancer
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06564844 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 228 locations. Find a study site near you:

Clinical Research Site

Gilbert, Arizona 85234 - United States

Status: WITHDRAWN

Clinical Research Site

Phoenix, Arizona 85054 - United States

Status: RECRUITING

Clinical Research Site

Prescott, Arizona 86301 - United States

Status: RECRUITING

Clinical Research Site

Tucson, Arizona 85724 - United States

Status: RECRUITING

Clinical Research Site

Duarte, California 91010 - United States

Status: RECRUITING

Clinical Research Site

Fountain Valley, California 92708 - United States

Status: RECRUITING

Clinical Research Site

Glendale, California 91204 - United States

Status: RECRUITING

Clinical Research Site

Irvine, California 92612 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Los Angeles, California 90089 - United States

Status: RECRUITING

Clinical Research Site

Los Angeles, California 90095 - United States

Status: NOT_YET_RECRUITING

And 218 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Non-small Cell Lung Cancer:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships